## STE: STERIS plc (Ireland) - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -3.4% below STRENGTH zone (3.0-6.0%); PEG 1.84 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-1.7% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($241.89)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 5, Bearish: 0)

**1. STERIS plc (NYSE:STE) Given Consensus Rating of "Moderate Buy" by Brokerages**
- Source: MarketBeat | 20251209T070237 | Bullish | Relevance: 98%
- Nine brokerages have given STERIS plc (NYSE:STE) a consensus "Moderate Buy" rating, with an average one-year target price of $273.50. The company recently surpassed Q1 earnings expectations, reporting an EPS of $2.47 against estimated $2.38, and revenue of $1.46 billion versus $1.43 billion. STERIS also announced a quarterly dividend of $0.63, while institutional investors hold approximately 94.7% of its stock.

**2. iSAM Funds UK Ltd Acquires Shares of 8,433 STERIS plc $STE**
- Source: MarketBeat | 20251209T135600 | Somewhat-Bullish | Relevance: 98%
-  iSAM Funds UK Ltd acquired 8,433 shares of STERIS plc, valued at approximately $2.03 million, during the second quarter. STERIS outperformed earnings expectations, reporting an EPS of $2.47 against an estimated $2.38, and announced a quarterly dividend of $0.63 per share. Despite positive financial results, company insiders have been net sellers, divesting 25,203 shares over the last 90 days.

**3. Frontier Capital Management Co. LLC Has $57.98 Million Stock Position in STERIS plc $STE**
- Source: MarketBeat | 20251211T130846 | Somewhat-Bullish | Relevance: 98%
-  Frontier Capital Management Co. LLC recently reduced its stake in STERIS plc (NYSE:STE) by 5.5%, bringing its total holdings to $57.98 million. Despite this, other institutional investors like Citigroup Inc. and JPMorgan Chase & Co. increased their positions, and the company also announced a quarterly dividend. Analysts have a "Moderate Buy" rating for STERIS with a consensus price target of $273.50.

**4. 13,829 Shares in STERIS plc $STE Acquired by Nebula Research & Development LLC**
- Source: MarketBeat | 20251211T125037 | Somewhat-Bullish | Relevance: 97%
- Nebula Research & Development LLC recently acquired 13,829 shares of STERIS plc (STE) valued at approximately $3.32 million, contributing to institutional ownership of 94.69%. Despite insider selling activity, STERIS reported strong Q2 results, exceeding EPS expectations and setting positive FY2026 guidance, alongside announcing a quarterly dividend. The company maintains an average analyst rating of "Moderate Buy" with a target price of $273.50.

**5. STERIS plc $STE Shares Bought by California Public Employees Retirement System**
- Source: MarketBeat | 20251211T094842 | Bullish | Relevance: 97%
- California Public Employees Retirement System increased its stake in STERIS plc by 4.7% to 166,605 shares, now valued at $40.02 million. STERIS reported strong quarterly earnings, beating analyst estimates, and announced a quarterly dividend of $0.63. Institutional investors now own 94.69% of the company, while insiders have sold approximately 25,203 shares worth $6.62 million in the last three months.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 11 ($0.79M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 46.4% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 12.4% (+0.4%)
- Blackrock Inc.: 8.9% (+1.3%)
- Massachusetts Financ: 4.9% (-7.7%)
- State Street Corpora: 4.4% (+4.0%)
- Morgan Stanley: 4.3% (+8.3%)

### Key Risks

1. Momentum deterioration: MRS_10 falling (-1.7% 5d) with bearish MACD, trend may be turning.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.84 elevated, pricing in significant growth expectations. Forward P/E 22.7x stretched relative to 9% growth. Balance sheet: strong liquidity (2.4x), low leverage (D/E 0.48). Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $24.9B |
| Beta | 1.01 |
| 52W Range | $200.98 - $268.60 |
| Short Interest | 1.4% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.84 |
| Forward P/E | 22.7 |
| Current P/E | 24.7 |
| YoY Growth | 9.1% |
| EPS Direction | STABLE |

### Technicals

MRS_10 deteriorating from -1.7% to -3.4% (-1.7% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 6.4pp (needs >3.0% for momentum thesis). Long-term uptrend intact (above SMA200 at 1.06x) but short-term weakness (below SMA20). MACD histogram bearish (-1.57), momentum weakening. RSI neutral at 43.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -3.38% (CS: 8) | Weak |
| RSI_14 | 42.9 | Neutral |
| MACD Histogram | -1.57 | Bearish |
| vs SMA20 | 0.970x | Below |
| vs SMA50 | 1.008x | Above |
| vs SMA200 | 1.059x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $252.49
- **Stop Loss:** $241.89 (4.2% risk)
- **Target:** $263.09 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 130
- **Position Value:** $32,823.70
- **Portfolio %:** 32.82%
- **Risk Dollars:** $1,380.00
- **Risk Per Trade:** 1.38%
- **Modifiers:** L1 115% | L2 120% | Combined 1.38x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.15x |
| L2 Sector | IGNITION (Zone D) | 1.20x |

*NORMAL regime with moderate risk appetite ahead of Fed decision. VIX at low 8th percentile signals complacency, but decent breadth and positive yield curve support selective positioning. Focus on quality names with earnings visibility.*

### Earnings

**Next:** 2026-02-04 (Est: $2.53)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.35 | $2.47 | +5.1% |
| 2025Q2 | $2.26 | $2.34 | +3.4% |
| 2025Q1 | $2.60 | $2.74 | +5.4% |
| 2024Q4 | $2.32 | $2.32 | -0.1% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*